Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold.
The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Two studies presented at the ESMO 2018 Congress demonstrated the efficacy of this combination in this patient population.
Web Exclusives published on December 12, 2018
Patients can be successfully managed with minimal opioid medication after urologic oncology surgery, said Kerri Stevenson, MN, NP-C, RNFA, CWOCN, Lead Advanced Practice Provider – Interventional Radiology, Stanford Health Care, CA, at the 2018 ASCO Quality Care Symposium. She presented results from a 4-month study conducted at Stanford Health Care. Over the course of the study, patients were able to decrease their opioid use after surgery by 46%, without compromising pain control.
Bone metastases are exceedingly common among patients with cancer and can significantly affect quality of life. Approximately 65% to 75% of patients with advanced breast or prostate cancer have bone metastases, which can lead to devastating complications...
On June 27, 2018, the FDA approved the combination of encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma), 2 new kinase inhibitors, for the treatment of patients with unresectable or metastatic melanoma and the BRAF V600E or BRAF V600K mutation, as detected by the companion diagnostic THxID BRAF Kit, which was approved on the same day.
Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology.
New cancer therapies have significantly improved survival outcomes, but have brought with them a wide range of oral toxicities, many of which are class-specific and otherwise new to the field of oncology, according to Nathaniel S. Treister, DMD, DMSc, Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA.
Chicago, IL—A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial. The addition of CMP-001 to pembrolizumab was well-tolerated, with encouraging antitumor responses in patients with metastatic melanoma that progressed with or after treatment with a PD-1 inhibitor.
Page 2 of 11
Results 11 - 20 of 108
Results 11 - 20 of 108